RankAlpha logo
Back to Rankings

CNTX

Context TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
View Chart
Current thesis
The best support in the packet is the June 15, 2026 CTIM-76 interim update: heavily pretreated PROC patients showed a 29% confirmed ORR and 57% disease control with low reported CRS at active doses, which is enough to keep clinical interest alive if Q3W follow-up data holds up [#PR-EARNINGS-2026-06-15].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CTIM-76 efficacy evidence is still early and based on a small active-dose ovarian dataset, so durability and reproducibility remain open questions.
Momentum
99
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.72 · Bull $1.40 · Bear $0.35
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.44
Why
Momentum99 · Δ7d -
Value41 · Δ7d -0.1
Sentiment74 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-17.8
Sentiment
74
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 99.1 / Value 41.1 / Sentiment 74.1

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$55.13M
Beta
1.91
Shares Out
91.88M
P/E (TTM) · Derived
-1.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.72
Rev YoY
-
EPS YoY
+89.6%
Gross Margin
-
Op Margin
-
Net Debt
-$65.88M
Current Ratio
8.92
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology